Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Conditions
Interventions
CC-92480
Bortezomib
+6 more
Locations
49
United States
Local Institution - 119
Denver, Colorado, United States
Local Institution - 104
Tampa, Florida, United States
Local Institution - 108
Atlanta, Georgia, United States
Local Institution - 112
Chicago, Illinois, United States
Local Institution - 107
Chicago, Illinois, United States
Local Institution - 117
Boston, Massachusetts, United States
Start Date
September 30, 2019
Primary Completion Date
November 30, 2026
Completion Date
November 30, 2026
Last Updated
November 29, 2024
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions